JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations
NCT06940401
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
42
Enrollment
INDUSTRY
Sponsor class
Conditions
NSCLC
Interventions
DRUG:
JS111 capsules (AP-L1898)
Sponsor
Suzhou Junjing BioSciences Co., Ltd.
Collaborators
[object Object]